Diagnostic characteristics of 149 adult study patients with Ph– CD19+ B-precursor ALL
| Characteristics . | N = 149 . |
|---|---|
| Sex, n (%) | |
| Male | 81 (54) |
| Female | 68 (4) |
| Age, median (range), y | 41 (18-65) |
| 18-40 | 69 (46) |
| 41-55 | 52 (35) |
| >55 | 28 (19) |
| BM blast cells, median (range), % | 90 (20-100) |
| WBC, median (range), ×109/L | 4.5 (10-474) |
| 0-30, n (%) | 123 (82.5) |
| >30-100 | 16 (10.7) |
| >100 | 10 (6.7) |
| Hemoglobin, median (range), g/dL | 9 (4.1-14) |
| Platelets, median (range), ×109/L | 48 (14-546) |
| Hepatomegaly, n (%) | 30 (34.5) |
| Splenomegaly, n (%) | 75 (56.8) |
| Lymphadenopathy, n (%) | 40 (27) |
| CNS involvement, n (%) | 12 (8) |
| ECOG PS, n (%) | |
| 0 | 97 (67) |
| 1 | 42 (29) |
| 2 | 6 (4.1) |
| N/A | 4 |
| Immunophenotype, n (%) | |
| Pro-B | 23 (16) |
| Common B | 114 (77) |
| Pre-B | 11 (7.4) |
| Undetermined | 1 |
| Genetics and cytogenetics∗, n (%) | |
| Normal genetics/cytogenetics | 56 (49) |
| Adverse | |
| KMT2A rearrangement/t(4;11) | 14/145 (9.6) |
| Other | 12† (10) |
| BCR::ABL1-like | 31/111 (27.9) |
| TP53 mutation | 10/98 (10.2) |
| Nonadverse | |
| TCF3::PBX1 rearrangement/t(1;19) | 5/145 (3.4) |
| Hyperdiploidy | 6 (5.2) |
| ETV6::RUNX1 rearrangement/t(12;21) | 1 (0.9) |
| Other | 21 (18) |
| Unknown | 34 (22.8) |
| Presentation risk class, n (%) | |
| SR | 85 (57) |
| HR | 29 (19) |
| VHR | 35 (23) |
| Characteristics . | N = 149 . |
|---|---|
| Sex, n (%) | |
| Male | 81 (54) |
| Female | 68 (4) |
| Age, median (range), y | 41 (18-65) |
| 18-40 | 69 (46) |
| 41-55 | 52 (35) |
| >55 | 28 (19) |
| BM blast cells, median (range), % | 90 (20-100) |
| WBC, median (range), ×109/L | 4.5 (10-474) |
| 0-30, n (%) | 123 (82.5) |
| >30-100 | 16 (10.7) |
| >100 | 10 (6.7) |
| Hemoglobin, median (range), g/dL | 9 (4.1-14) |
| Platelets, median (range), ×109/L | 48 (14-546) |
| Hepatomegaly, n (%) | 30 (34.5) |
| Splenomegaly, n (%) | 75 (56.8) |
| Lymphadenopathy, n (%) | 40 (27) |
| CNS involvement, n (%) | 12 (8) |
| ECOG PS, n (%) | |
| 0 | 97 (67) |
| 1 | 42 (29) |
| 2 | 6 (4.1) |
| N/A | 4 |
| Immunophenotype, n (%) | |
| Pro-B | 23 (16) |
| Common B | 114 (77) |
| Pre-B | 11 (7.4) |
| Undetermined | 1 |
| Genetics and cytogenetics∗, n (%) | |
| Normal genetics/cytogenetics | 56 (49) |
| Adverse | |
| KMT2A rearrangement/t(4;11) | 14/145 (9.6) |
| Other | 12† (10) |
| BCR::ABL1-like | 31/111 (27.9) |
| TP53 mutation | 10/98 (10.2) |
| Nonadverse | |
| TCF3::PBX1 rearrangement/t(1;19) | 5/145 (3.4) |
| Hyperdiploidy | 6 (5.2) |
| ETV6::RUNX1 rearrangement/t(12;21) | 1 (0.9) |
| Other | 21 (18) |
| Unknown | 34 (22.8) |
| Presentation risk class, n (%) | |
| SR | 85 (57) |
| HR | 29 (19) |
| VHR | 35 (23) |
BCR::ABL1-like gene predictor model and TP53 mutation (undetectable in patients with Ph-like ALL) were not included in study risk classification.
BM, bone marrow; ECOG PS, Eastern Cooperative Oncology Group performance score; N/A, not available.
Incidence of individual abnormalities, with number of evaluable patients when necessary.
Other adverse includes the following: +8 (n = 1), complex karyotype (n = 8), del6q (n = 1), and low hypodiploidy (n = 2).